

WORLD JOURNAL OF PHARMACEUTICAL RESEARCH

SJIF Impact Factor 5.045

Volume 3, Issue 4, 1784-1797.

Research Article

ISSN 2277 - 7105

SODIUM DODECYL SULPHATE POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE) PATTERN OF PRE-ANTI RETROVIRAL THERAPY(PRE ART) AND ANTI RETROVIRAL THERAPY(ART) TREATED MALE AND FEMALE HIV/AIDS PATIENTS

*S.Vijayalakshmi¹, Dr.C.Chandran², Dr.MP.Saravanan³, Dr.S.Dhanapaul⁴

¹Research scholar, ²Associate professor, PG and Research Department of Botany and Microbiology, A.V.V.M Sri Pushpam College, Poondi, Thanjavur ³Associate professor, ⁴Head of the Department of Microbiology KAPV Government Medical College, Trichy

Article Received on 05 May 2014, Revised on 01 June 2014, Accepted on 25 Jun 2014

*Correspondence for Author

S.Vijayalakshmi,

Research Scholar, Department of Botany and Microbiology, A.V.V.M Sri Pushpam College, Poondi-613503. Than javur.

ABSTRACT

Human immunodeficiency virus (HIV) causes **Acquired immune deficiency syndrome.** Human immune system is mainly affected by HIV. HIV transmitted through anal, vaginal or oral sex, blood transfusion, contaminated needles, exchange between mother and baby during pregnancy, breastfeeding, or other exposure to one of the above bodily fluids. Currently no vaccine is available for AIDS and HIV. Antiretroviral treatment reduces the mortality and the morbidity of HIV infection. HIV positive serum was collected from 5 group of patients. CD4 count was measured using flowcytometry. Serum proteins were separated by SDS – PAGE. In the SDS – PAGE, Alpha1 antitrypsin, Pre albumin, Albumin, Transferrin, Beta zone and Gamma

zone was observed.3 year after the treatment of ART protein levels are increased in the male samples.

KEYWORDS: HIV, serum protein, ART, CD4 count.

INTRODUCTION

Human immunodeficiency virus (HIV) cause **Acquired immuno deficiency syndrome**. AIDS was first recognized by the U.S. (Centers for Disease Control and Prevention in 1981) causative organism of AIDS was identified in the early 1980. (Gallo RC (2006)). Young

people (under 25 years old) account for half of all new HIV infections worldwide. In developing and transitional countries, 9.7 million people were in immediate need of life-saving AIDS drugs; of these, only 2.99million (31%) are receiving the drugs.

DEFINITION

In 1993, the CDC expanded their definition of AIDS to include all HIV positive people with a CD4 $^{+}$ T cell count below 200 per μ L of blood or 14% of all lymphocytes. (The CDC, (1993), Retrieved on 2006-02-09).

Antiretroviral drugs

Antiretroviral drugs are medications for the treatment of infection by retroviruses, primarily HIV. They are not a cure for HIV. They lower the level of the virus in the blood. This allows the immune system to recover (the CD4 count may increase). People who are infected with HIV do not need antiviral treatment while their immune system is still strong (stages 1, 2 and 3). Antiretroviral treatment is only needed once the immune system has become weak. These medicines will not work effectively if they are not taken correctly.

Antiretroviral drugs

Zidovudin, Lamivudin, Zidovudin+ Lamivudin, Nevirapine.

MATERIALS AND METHODS

The present study entitled "Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) pattern of Pre-Anti Retroviral Therapy(Pre ART) and Anti Retroviral Therapy(ART) treated male and female HIV/AIDS patients" was carried out in the Department of Biochemistry and Microbiology, KAPV Government medical college, Trichy during March 2009 to August 2009.

Sample collection

Data on HIV infected patients were collected from ART centre of AGM Government hospital, Trichy. Before collecting the blood samples, explain the details about the project to the patients. Blood sample was collected from the interested candidates only. HIV-positive samples were collected with **universal precaution measures.**

Patients are categorized into 5 groups

- 1. Pre-ART-HIV-Positive patient not yet started with ART (55).
- 2. ART group 1- on treatment for 6months (6)

- 3. ART group 2- on treatment for 1 year (11)
- 4. ART group 3- on treatment for 2 year (13)
- 5. ART group 4- on treatment for 3 year (10)

Two sets of samples will be collected


- a. EDTA sample-CD4 count.
- b. Clolted sample-SDS-PAGE


Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis analysis of Proteins


| Solutions | Separating Gel Mixture | Stacking Gel Gel Mixture |
|--|-------------------------------|--------------------------|
| Acrylamide monomer stock solution | 10ml | 1.33ml |
| 4X Separating gel buffer,pH-8.8/4X Stacking gel buffer, pH-6.8 | 7.5ml | 2.5ml |
| 10% SDS solution | 0.3ml | 0.1ml |
| Distilled water | 12.1ml | 50μl |
| 10% APS | 150µl | 5 μl |
| TEMED | 10 μl | 6.0ml |


Separating gel was cast as per the the composition. Ammonium Per Sulphate (APS) and TEMED were added just prior to pouring the gel. The solution was poured and allowed to polymerize between two glass plates. The gel was overlaid carefully with a film of distilled water. After polymerization, the water layer was removed and stacking gel was poured. The comb was placed on the top. The comb was carefully removed from the wells after polymerization of the stacking gel. The wells are washed with tank buffer. Equal volume of sample and 2X sample buffer was mixed and heat 10 to 15 min at 90°c. These samples are kept in ice up to sample loading 20µl of the samples were then carefully loaded into the wells. 125ml of electrode buffer was poured in the inner chamber and 200ml of buffer in the outer chamber. Gels were run at a constant current 100voltage for 90min (or) till the dye front reached the bottom of the gel. The gel was removed carefully from the plates and was placed in staining. Solution coo massive brilliant blue overnight. The gel was replaced into the destaining solution for one day and washed and it was expressed as kilo Dalton.


RESULT



































ART - 2 YEAR

A24 A25 A26 A27 A28 A29

Gamma Zone

Beta Zone

Transferrin

Albumin

Prealbumin

Alpha-1-antitrypsin

ART - 2 YEAR

A18 A19 A20 A21 A22 A23

Gamma Zone


Beta Zone


Transferrin

Albumin

Prealbumin

Alpha-1-antitrypsin





CD4 Enumeration of pre ART patients

| S.No | Reference No | Patient ID No | Age & Sex | CD4 count |
|------|-----------------|------------------|-----------|-----------|
| 1 | P1 | 3377 | 25/F | 31 |
| 2 | P2 | 3371 | 43/M | 522 |
| 3 | P3 | 3367 | 34/M | 105 |
| 4 | P4 | 3366 | 23/F | 354 |
| 5 | P5 | 3365 | 30/F | 710 |
| 6 | P6 | 3361 | 22/F | 407 |
| 7 | P7 | 3359 | 42/M | 1 |
| 8 | P8 | 3357 | 27/F | 196 |
| 9 | P9 | 3356 | 21/F | 587 |
| 10 | P10 | 3355 | 22/F | 596 |
| 11 | P11 | 3354 | 32/M | 112 |
| 12 | P12 | 3353 | 45/M | 303 |
| 13 | P13 | 3352 | 37/F | 815 |
| 14 | P14 | 3351 | 45/M | 219 |
| 15 | P15 | 3350 | 36/F | 198 |
| 16 | P16 | 3342 | 40/F | 454 |
| 17 | P17 | 3335 | 12/M | 455 |
| 18 | P18 | 3635 | 45/F | 436 |
| 19 | P19 | 3355 | 23/F | 596 |
| 20 | P20 | 3334 | 45/F | 336 |
| 21 | P21 | 3637 | 37/F | 595 |
| 22 | P22 | 3642 | 40/M | 448 |
| 23 | P23 | 3643 | 24/F | 399 |
| 24 | P24 | 3647 | 52/F | 484 |
| 25 | P25 | 3648 | 46/M | 374 |
| 26 | P26 | 3349 | 20/M | 388 |
| 27 | P27 | 3616 | 25/F | 343 |
| 28 | P28 | 3633 | 40/M | 711 |
| 29 | P29 | 3614 | 41/M | 205 |
| 30 | P30 | 3348 | 29/F | 395 |
| 31 | P31 | 3607 | 32/F | 366 |
| 32 | P32 | 3605 | 40/F | 360 |
| 33 | P33 | 3604 | 30/F | 289 |
| 34 | P34 | 3603 | 23/F | 312 |
| 35 | P35 | 3601 | 28/F | 211 |
| 36 | P36 | 3344 | 32/M | 484 |
| 37 | P37 | 3341 | 25/F | 440 |
| 38 | P38 | 3340 | 40/M | 513 |
| 39 | P39 | 3339 | 41/M | 503 |
| 40 | P40 | 3332 | 23/F | 414 |
| 41 | P41 | 3650 | 36/F | 728 |
| 42 | P42 | 3370 | 35/F | 900 |
| 43 | P43 | 3375 | 27/F | 388 |
| 44 | P44 | 3379 | 30/M | 651 |

| 45 | P45 | 3378 | 24/F | 632 |
|----|-----|------|------|-----|
| 46 | P46 | 3613 | 65/M | 254 |
| 47 | P47 | 3611 | 33/M | 114 |
| 48 | P48 | 3610 | 27/M | 126 |
| 49 | P49 | 3636 | 26/F | 235 |
| 50 | P50 | 3622 | 30/M | 172 |
| 51 | P51 | 3634 | 40/F | 809 |
| 52 | P52 | 3329 | 32/F | 175 |
| 53 | P53 | 3374 | 47/M | 67 |
| 54 | P54 | 3373 | 50/M | 211 |


CD4 Enumeration of ART Patients

| S.NO | REFERENCE NO | PATIENT ID NO | AGE&SEX | CD4 COUNT |
|------|--------------|---------------|---------|-----------|
| 1 | A1 | 3362 | 32/F | 394 |
| 2 | A2 | 3608 | 62/F | 132 |
| 3 | A3 | 3612 | 17/M | 374 |
| 4 | A4 | 3363 | 47/F | 400 |
| 5 | A5 | 3330 | 32/F | 274 |
| 6 | A6 | 3343 | 60/F | 135 |
| 7 | A7 | 3336 | 43/M | 408 |
| 8 | A8 | 3347 | 65/M | 334 |
| 9 | A9 | 3358 | 38/M | 315 |
| 10 | A10 | 3360 | 58/M | 211 |
| 11 | A11 | 3621 | 26/F | 241 |
| 12 | A12 | 3649 | 47/M | 176 |
| 13 | A13 | 3615 | 30/F | 569 |
| 14 | A14 | 3609 | 25/F | 268 |
| 15 | A15 | 3620 | 30/M | 222 |
| 16 | A16 | 3619 | 33/M | 188 |
| 17 | A17 | 3364 | 20/F | 689 |
| 18 | A18 | 3380 | 24/F | 535 |
| 19 | A19 | 3328 | 3/F ch | 1397 |
| 20 | A20 | 3338 | 67/M | 220 |
| 21 | A21 | 3331 | 4/M ch | 535 |
| 22 | A22 | 3641 | 3/F ch | 200 |
| 23 | A23 | 3638 | 30/M | 575 |
| 24 | A24 | 3333 | 65/F | 145 |
| 25 | A25 | 3645 | 38/M | 945 |
| 26 | A26 | 3639 | 35/M | 630 |
| 27 | A27 | 3644 | 45/M | 312 |
| 28 | A28 | 3632 | 49/M | 261 |
| 29 | A29 | 3640 | 14/M | 570 |
| 30 | A30 | 3376 | 39/M | 205 |
| 31 | A31 | 3345 | 42/F | 603 |
| 32 | A32 | 3618 | 39/M | 638 |
| 33 | A33 | 3646 | 50/M | 536 |
| 34 | A34 | 3631 | 50/M | 466 |


| 35 | A35 | 3337 | 32/F | 665 |
|----|-----|------|------|------|
| 36 | A36 | 3368 | 46/M | 1084 |
| 37 | A37 | 3606 | 47/M | 99 |
| 38 | A38 | 3617 | 42/M | 63 |
| 39 | A39 | 3372 | 35/M | 292 |

Comparative values of protein level in pre ART Male and Female Samples

| Name of | ART 3 YEAR (%) – MALE | | | | ART 3 YEAR (%) - FEMALE | | | |
|-------------------------|-----------------------|----------|-----|--------|-------------------------|----------|-----|-------|
| bands /level | High | Moderate | Low | Absent | Hig | Moderate | Low | Absen |
| | | | | | h | | | t |
| Alpha 1 Anti trypsin | 0 | 11 | 0 | 8 | 0 | 0 | 0 | 100 |
| Pre Albumin | 33 | 11 | 0 | 5 | 0 | 0 | 0 | 100 |
| Albumin | 78 | 0 | 0 | 2 | 0 | 0 | 100 | 0 |
| Transferrin | 11 | 0 | 0 | 8 | 0 | 0 | 0 | 100 |
| Beta zone | 3 | 3 | 56 | 0 | 1 | 100 | 0 | 0 |
| Gamma zone | 56 | 11 | 22 | 1 | 100 | 0 | 0 | 0 |




Comparative values of protein level in ART 6 months Male and Female samples




Comparative values of protein level in ART 1 year Male and Female


| Name of | ART 2 YEAR (%) – MALE | | | | ART 2 YEAR (%) - FEMALE | | | |
|-------------------------|-----------------------|----------|-----|--------|-------------------------|----------|-----|-------|
| bands /level | High | Moderate | Low | Absent | Hig | Moderate | Low | Absen |
| | | | | | h | | | t |
| Alpha 1 Anti trypsin | 10 | 20 | 0 | 70 | 0 | 67 | 0 | 33 |
| Pre Albumin | 20 | 40 | 10 | 30 | 0 | 67 | 0 | 33 |
| Albumin | 70 | 10 | 0 | 20 | 67 | 33 | 0 | 0 |
| Transferrin | 30 | 0 | 0 | 70 | 33 | 0 | 0 | 67 |
| Beta zone | 60 | 20 | 10 | 10 | 0 | 67 | 33 | 0 |
| Gamma zone | 20 | 60 | 0 | 20 | 33 | 67 | 0 | 0 |



Comparative values of protein level in ART 2 year Male and Female samples



Comparative values of protein level in 3 year ART Male and Female samples



Comparative values of protein level in pre ART Male and Female samples

PRE ART

Maximum number of pre ART female samples containing alpha 1 antitrypsin, albumin, gamma zone than male samples. Maximum number of male samples containing pre albumin.

ART-6 MONTHS

Maximum number of ART-6 months treated female samples containing alpha 1 antitrypsin, pre albumin, transferrin , beta zone, gamma zone. Maximum number of male samples containing albumin.

ART-1 YEAR

Maximum number of ART -1 year treated female samples containing transferrin and beta zone. Maximum number of male samples containing alpha 1 antitrypsin, pre albumin, albumin, gamma zone.

ART-2 YEAR

Male samples only containing all the proteins in maximum numbers.

ART-3 YEAR

Male samples only containing all the proteins in maximum numbers.

DISSCUSION

Alpha 1 antitrypsin

Alpha 1 antitrypsin deficiency is an inherited disorder that can cause lung disease in adults and liver disease in adults and children. Not having enough alpha 1 antitrypsin puts risk of emphysema or liver problems. Alpha-1 antitrypsin may play a protective role in HIV-1 infection (Potthoff *et al.*, 2007).

TRANSTHYRETIN or PREALBUMIN

In medicine, nutritional status can be assessed by measuring concentrations of transthyretin in the blood. In adults, prealbumin screening has been useful in assessing protein status in AIDS - or cancer-related cachexia, as well as nutritional status in nursing home residents. Higher prealbumin concentrations were associated with vascular access—related hospitalization.

ALBUMIN

Albumin is essential for maintaining the osmotic pressure needed for proper distribution of body fluids between intravascular compartments and body tissues.levels of serum albumin were only moderately related to traditional markers of HIV disease progression, including CD4 cell count, viral load and body mass index.The investigators note that "even though serum albumin is not a specific marker of HIV-1 infection, it is one of the strongest independent predictors of mortality."In women with severe immune damage, and a CD4 cell count below 200cells/mm³, the risk of death was increased eight-fold in those with serum albuminbelow 35 mg/L compared to those with a level above 42 mg/L.

TRANSFERRIN

Transferrin is also associated with the innate immune system. **Transferrin** is a blood plasma protein for iron ion delivery .A patient with an increased serum transferrin level often suffers from iron deficiencyanemia. (*Macedo MF*, *de Sousa M* (March 2008).An anemia in the heart and liver that leads to many complications including heart failure.

GAMMA ZONE

IgG, IgA, IgD, IgE, IgM .Decreased or absent IgA termed selective IgA defiency, can be clinically significant immunodefiency. Neisseria gonorrhoeae destroys IgA.IgM antibodies appear early in the course of an infection.**Iron deficiency in populations with high levels of infection and HIV**, an HIV test is necessary to interpret any tests of iron deficiency.

Immunoglobulin

low serum transferrin concentration in children with the nephrotic syndrome is related to their decreased immunoglobulin concentrations. Decreased serum transferrin concentrations might limit immunoglobulin synthesis.

IgA

The frequency is increased in children with recurrent respiratory tract infections especially in relatives patients with immunoglobulin deficiencies. (J. Litzman *et al.*, (2000)).

IgE

Elevated serum immunoglobulin E (IgE) and increased prevalence of atopy is reported in patients infected with human immunodeficiency virus (HIV). In advanced stages of HIV, elevated serum IgE may be specific for antigens other than those known as allergens. (Corinna S *et al.*, (2006)).

CONCLUSION

HIV patients are susceptible to opportunistic infections due to the deficiency of proteins.ART improves the CD4 count and proteins levels. 3 year after the treatment of ART, protein levels are increased in the male samples.

REFERENCES

- 1 Antony S. Dimitrov, John M. Louis, Carole A. Bewley, G. Marius Clore, and RobertBlumenthal. Conformational Changes in HIV-1 gp41 in the Course of HIV-1 Envelope Glycoprotein-Mediated Fusion and Inactivation Biochemistry. 2005 September 20; 44(37): 12471–12479. doi: 10.1021/bi051092d.
- 2 Baria F. et al., India Today (15th March 1997), 'AIDS striking home'
- 3 Burton, D. R., and D. C. Montefiori. 1997. The antibody response in HIV-1 infection. AIDS 11(Suppl. A):S87-S98.
- 4 Campbell GR, Pasquier E, Watkins J, et al. (2004). "The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis". *J. Biol. Chem.* 279 (46): 48197–48204. doi:10.1074/jbc.M406195200. PMID 15331610
- 5 Doms RW, Moore JP. HIV-1 membrane fusion: Targets of opportunity. *J Cell Biol.* 2000;151:F9–F14.
- 6 Feldman C (2005). "Pneumonia associated with HIV infection". Curr. Opin. Infect. Dis. 18 (2): 165–170. PMID 15735422
- 7 Gallo RC (2006). "A reflection on HIV/AIDS research after 25 years". Retrovirology 3: 72.doi:10.1186/1742-4690-3-72.PMID17054781. http://www.retrovirology.com/content/3//72
- 8 Hammonds, J., X. Chen, L. Ding, T. Fouts, A. De Vico, J. zur Megede, S. Barnett, and P. Spearman. 2003. gp 120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core. Virology 314:636-649.
- 9 Potthoff, Anja V; Münch, Jan; Kirchhoff, Frank; Brockmeyer, Norbert H; and the Competence Network for HIV/AIDS ., HIV infection in a patient with alpha-1 antitrypsin deficiency Official journal of the international AIDS society 2007 Volume 21 Issue 15 p 2115-2116